Last week in the Ukraine, the Association of Pharmaceutical Research and Development (APRaD) and the American Chamber of Commerce (ACC) in Ukraine issued a join position paper regarding the problems with reforming the provision of diabetes mellitus patients with the necessary medicines.
The key moments for successful realization of Pilot project on implementing of the state regulation of prices on insulin preparations are, according to the APRaD, as follows:
1. When using the comparative approach (referencing with other countries), it is necessary to create the same conditions which exist in other countries with the effective system of treatment expenses reimbursement, namely: a) to change the tender system of drug purchase for the reimbursement system; b) eliminate administrative barriers for doctors to prescribe innovative analogue insulins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze